why choose us

Clinical Trials Search

Showing 10,670 of 132,366 result(s)
Early Detection of Lung Cancer With Machine Learning Based on Routine Clinical Investigations

Status: NOT_YET_RECRUITING

Condition: Adenocarcinoma of Lung; Bronchial Neoplasms; Early Detection of Cancer; Machine Learning

Interventions: No interventions.

Date: 2023-06-08

Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions

Status: NOT_YET_RECRUITING

Condition: Neoplasms

Interventions: 25-items questionnaire

Date: 2023-06-08

Decitabine for Poor Graft Function Post Allo-HSCT

Status: NOT_YET_RECRUITING

Condition: Poor Graft Function

Interventions: Decitabine 6 mg;m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)

Date: 2023-06-08

The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation

Status: NOT_YET_RECRUITING

Condition: Thrombotic Disorder

Interventions: 8g;d (>=45kg); 200mg;kg.d
(<45kg), intravenously for at least 4 hours, day -9 to day +45

Date: 2023-06-08

A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults

Status: NOT_YET_RECRUITING

Condition: Healthy Participants

Interventions: PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.

Date: 2023-06-08

Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis

Status: NOT_YET_RECRUITING

Condition: Ulcerative Colitis

Interventions: CU104 will administer the study drug once a day after a meal

Date: 2023-06-08

Safeguarding the Brain of Our Smallest Children-IIIv (SafeBoosC-IIIv)

Status: NOT_YET_RECRUITING

Condition: Hypoxia

Interventions:

The experimental group will receive cerebral oximetry added to usual care, if possible before or, as soon as possible and within six hours after me

Date: 2023-06-08

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia

Status: NOT_YET_RECRUITING

Condition: Congenital Adrenal Hyperplasia

Interventions: CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.

Date: 2023-06-08

Compare Smokers' Appraisal of Proposed Plain Packs and Existing Cigarette Packs

Status: NOT_YET_RECRUITING

Condition: Health Risk Behaviors

Interventions:

Date: 2023-06-08

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Status: NOT_YET_RECRUITING

Condition: Melanoma

Interventions: ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.

Date: 2023-06-08